Concepedia

Author

Andrea Perrone

Dana-Farber Cancer InstituteORCID

Also Known As

A Perrone, A. Perrone, Andrea M. Perrone, Andrea Marie Perrone, Andrea PERRONE, Andrea Perrone, Perrone, Andrea

145

Publications

4.6K

Citations

21

H-Index

89

Concepts

All Affiliations

Dana-Farber Cancer InstituteThe University of Texas MD Anderson Cancer CenterMerck & Co., Inc., Rahway, NJ, USA (United States)Memorial Sloan Kettering Cancer CenterAngeles Clinic and Research Institute
AP

About

Andrea Perrone is an author at Dana-Farber Cancer Institute specializing in medicine, immunology, and autoimmune disease.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

10

10

411

2

Engineering

4

4

71

3

Health Sciences

2

2

60

4

Business

1

1

25

5

Management

1

1

25

Andrea Perrone

×

24

Publications

2K

Citations

18

H-Index

YearCitations

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

F. Stephen Hodi, Wen-Jen Hwu, Richard Kefford,

Journal of Clinical Oncology

2016

742

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

Richard W. Joseph, Jeroen Elassaiss‐Schaap, Richard Kefford,

Clinical Cancer Research

2018

302

Peripheral blood gene expression profiling in rheumatoid arthritis

Franak Batliwalla, E C Baechler, Xu Xiao,

Genes and Immunity

2005

153

Epigenetic Multiple Ligands: Mixed Histone/Protein Methyltransferase, Acetyltransferase, and Class III Deacetylase (Sirtuin) Inhibitors

Antonello Mai, Donghang Cheng, Mark T. Bedford,

Journal of Medicinal Chemistry

2008

132

Measurement of Tumor Volumes Improves RECIST-Based Response Assessments in Advanced Lung Cancer

P. David Mozley, Claus Bendtsen, Binsheng Zhao,

Translational Oncology

2012

111

Innovative Poly (Vinylidene Fluoride) (PVDF) Electrospun Nanofiber Membrane Preparation Using DMSO as a Low Toxicity Solvent

Francesca Russo, Claudia Ursino, Elisa Avruscio,

Membranes

2020

88

Synthesis and Biological Validation of Novel Synthetic Histone/Protein Methyltransferase Inhibitors

Antonello Mai, Sérgio Valente, Donghang Cheng,

ChemMedChem

2007

56

Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.

F. Stephen Hodi, Antoni Ribas, Adil Daud,

Journal of Clinical Oncology

2014

40

KEYNOTE-040: A phase III randomized trial of pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer.

Ezra E.W. Cohen, Jean‐Pascal Machiels, Kevin J. Harrington,

Journal of Clinical Oncology

2015

36

Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475.

Richard W. Joseph, Jeroen Elassaiss‐Schaap, Jedd D. Wolchok,

Journal of Clinical Oncology

2014

35

Page 1